HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vingerhoets, F. J.G. Articles by Calne, D. B. Search for Related Content PubMed PubMed Citation Articles by Vingerhoets, F. J.G. Articles by Calne, D. B.

Reproducibility of Fluorine-18-6-Fluorodopa Positron Emission Tomography in Normal Human Subjects

Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia, Vancouver, British Columbia
Department of Medical Physics, University of Wisconsin, Madison, Wisconsin

Correspondence: For correspondence or reprints contact: Barry J. Snow, MD, Neurodegenerative Disorders Centre, University Hospital—UBC Site, 2211 Westbrook Mall, Vancouver, BC V6T 2B5, Canada.

ABSTRACT

Fluorine-18-6-fluorodopa (FD) positron emission tomography (PET) is established for measuring nigrostriatal dopaminergic function. This is despite the absence of data on the reproducibility of results. Methods: With an ECAT 953B/31 tomograph, we performed two or three repeated FD PET scans in 10 normal subjects to measure the scan-to-scan variation in the total striatal uptake rate constant (Ki). Results: We found a scan-to-scan standard deviation (s.d.) of 8.7% of the mean. The between-subject s.d. was 26% of the mean, resulting in a reliability coefficient of 90%. Analysis of the variation in the components contributing to Ki showed a reliability varying from 77% to 86% (depending on the different time points analyzed) for emission data measured by the PET camera. The reliability of the blood radioactivity time course, as reflected by the stretch time, varied from 43% to 81%. The overall reliability for the correction of the blood time course for metabolites of FD was 71%. Variation in the blood radioactivity contributed to the variability of Ki by 50% more than the metabolite correction and by 200% more than the emission data. Conclusion: The striatal Ki is a reliable measurement; it has a 95% chance of lying within ±18% of its value for an individual normal subject.

Key Words: fluorodopa • PET Imaging

This article has been cited by other articles:

				A. Kumar, S. Mann, V. Sossi, T. J. Ruth, A. J. Stoessl, M. Schulzer, and C. S. Lee [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease Brain, December 1, 2003; 126(12): 2648 - 2655. [Abstract] [Full Text] [PDF]

				L. N. Yatham, P. F. Liddle, I-S. Shiah, R. W. Lam, E. Ngan, G. Scarrow, M. Imperial, J. Stoessl, V. Sossi, and T. J. Ruth PET Study of [18F]6-Fluoro-L-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium Am J Psychiatry, May 1, 2002; 159(5): 768 - 774. [Abstract] [Full Text] [PDF]

				P. K. Morrish, P. Vieregge, J. Hagenah, I. Heberlein, C. Klein, and H.-P. Ludin Parkinson's disease in twins Neurology, April 25, 2000; 54(8): 1710 - 1711. [Full Text] [PDF]

				B. J Snow, F. J G Vingerhoets, J W. Langston, J. W Tetrud, V. Sossi, and D. B Calne Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism J. Neurol. Neurosurg. Psychiatry, March 1, 2000; 68(3): 313 - 316. [Abstract] [Full Text] [PDF]

				K Ito, P K Morrish, J S Rakshi, T Uema, J Ashburner, D L Bailey, K J Friston, and D J Brooks Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 754 - 758. [Abstract] [Full Text]

				R. A. Hauser, T. B. Freeman, B. J. Snow, M. Nauert, L. Gauger, J. H. Kordower, and C. W. Olanow Long-term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease Arch Neurol, February 1, 1999; 56(2): 179 - 187. [Abstract] [Full Text] [PDF]

				P K Morrish, J S Rakshi, D L Bailey, G V Sawle, and D J Brooks Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET J. Neurol. Neurosurg. Psychiatry, March 1, 1998; 64(3): 314 - 319. [Abstract] [Full Text] [PDF]

				J. H. Kordower, T. B. Freeman, B. J. Snow, F. J.G. Vingerhoets, E. J. Mufson, P. R. Sanberg, R. A. Hauser, D. A. Smith, G. M. Nauert, D. P. Perl, et al. Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease N. Engl. J. Med., April 27, 1995; 332(17): 1118 - 1124. [Abstract] [Full Text] [PDF]